Background Polymorphonuclear leukocytes (PMNs) have been shown to mediate coronary vascular and myocardial tissue injury after coronary artery ischemia and reperfusion. Previous studies using specific monoclonal antibodies directed against P-selectin and L-selectin have demonstrated the involvement of the selectin family of glycoproteins in the early phase of PMN-induced myocardial ischemia-reperfusion injury. We examined the effects of a novel oligosaccharide analog of sialyl Lewisx (SLex), which blocks both P-selectin and E-selectin in an acute canine model of myocardial ischemia and reperfusion.
Previous studies using specific monoclonal antibodies directed against P-selectin and L-selectin have demonstrated the involvement of the selectin family of glycoproteins in the early phase of PMN-induced myocardial ischemia-reperfusion injury. We examined the effects of a novel oligosaccharide analog of sialyl Lewisx (SLex), which blocks both P-selectin and E-selectin in an acute canine model of myocardial ischemia and reperfusion. Methods and Results Anesthetized, open-chest dogs were subjected to 1.5 hours of left circumflex coronary artery (LCx) occlusion followed by 4.5 hours of reperfusion and randomly received the SLeX analog CY-1503 (5 mg/kg IV), the nonfucosylated analog of CY-1503, SLN (5 mg/kg IV), or saline 5 minutes before reperfusion. The investigators were blinded to the treatment until all the data analysis was completed. All three groups of dogs exhibited similar and severe reductions in transmural myocardial blood flow in the LCx region as well as pronounced myocardial contractile dysfunction during occlusion, suggesting comparable degrees of myocardial ischemia. After reperfusion, dogs receiving saline (n=6) displayed an enhanced degree of myocardial injury that was evidenced by a dramatic elevation in plasma creatine kinase (CK) activity, PMN accumulation, and myocardial necrosis. Plasma CK activity increased from 1.9±0.5 IU/,g protein at baseline to 73.0± 11.0 IU/,ug protein (P<.001) at 4.5 hours of reperfusion he reperfusion of ischemic myocardial tissue initiates an inflammatory cascade characterized by the elaboration of cytokines, the expression of endothelial cell adhesion molecules, the adhesion of neutrophils (PMNs) to the coronary endothelium, PMN activation, and finally PMN-mediated myocardial cell injury and necrosis.1,2 Studies aimed at the removal3,4 or inhibition5-8 of PMNs have demonstrated a dramatic reduction in postischemic myocardial injury and provide evidence that PMNs play a major role in the sequelae of myocardial reperfusion injury.
and myocardial PMN accumulation, as measured by cardiac myeloperoxidase (MPO) activity, and was significantly enhanced (P<.01) within the necrotic zone compared with the nonischemic zone (4.3±0.6 versus 0.7±0.1 U/100 mg tissue). After 4.5 hours of reperfusion, 36% of the myocardium within the ischemic zone and 17% of the left ventricle became necrotic in the dogs receiving saline. Treatment with CY-1503 (n=6) significantly (P<.05) blunted plasma CK activity by more than 50% throughout the reperfusion period, reduced necrotic zone PMN accumulation by 63% (P<.05), and reduced myocardial necrosis in the area at risk by 65% (P<.01) and by 72% within the left ventricle (P<.01). In contrast, administration of the nonfucosylated analog of CY-1503, SLN (n=6), failed to exert any detectable cardioprotective effects after myocardial ischemia and reperfusion.
Conclusions Our results provide strong evidence that treatment with a unique carbohydrate analog of SLeX, CY-1503, significantly reduces the degree of myocardial injury associated with coronary artery ischemia and reperfusion. The profound cardioprotection appears to be related to a reduction in PMN accumulation within the ischemic-reperfused myocardium. Additional studies investigating more-prolonged periods of reperfusion are required to determine whether CY-1503 treatment merely delays the onset or actually reduces the full extent of myocardial necrosis after ischemia and reperfusion. (Circulation. 1994; 90:2390 -2401 Key Words * blood flow * endothelium * myocardial contraction * leukocytes Adhesion of PMNs to the ischemic-reperfused coronary endothelium is thought to be a prerequisite for PMN-mediated myocardial reperfusion injury and involves the interaction of a number of adhesion molecules acting in concert. 1 The initial interaction between PMNs and endothelial cells is characterized by PMN "rolling" along the endothelium and is believed to be mediated by the selectin family of glycoprotein adhesion molecules, including P-selectin, E-selectin, and L-selectin.9-11 Firm adhesion of activated PMNs to the endothelium occurs secondary to the selectin-induced tethering of PMNs to endothelial cells and is largely a result of interactions between the PMN P2 integrins (CD11a/ CD18, CD11b/CD18, and CD11c/CD18) and endothelial intercellular adhesion molecule-1 (ICAM-1).l Previous animal studies have clearly demonstrated that inhibition of CD1867 and ICAM-112-14 with blocking monoclonal antibodies (MAbs) significantly reduces the degree of myocardial injury that results from coronary artery occlusion and reperfusion. Furthermore, administration of a MAb directed against P-selectinl5'16 can preserve the coronary circulation and reduce myocardial cell injury after ischemia and reperfusion. At present, very little is known concerning the involvement of E-selectin in myocardial injury after coronary artery ischemia and reperfusion. A recent study by Winquist et al12 demonstrated marked coronary endothelial immunostaining for E-selectin in a primate model of 90 minutes of coronary occlusion and 4 hours of reperfusion. However, administration of a specific E-selectin MAb 30 minutes before ischemia failed to exert any cardioprotective actions. As a result, the functional significance of E-selectin expression by the coronary circulation after myocardial ischemia and reperfusion remains unclear.
Several lines of experimental evidence suggest that the functional ligands for P-, L-, and E-selectin on opposing cells might be carbohydrate structures that contain both sialic acid and fucose. 17 were then administered directly into the LCx coronary artery in a completely random sequence. All drugs were freshly solubilized in normal saline and were slowly injected through the coronary catheter, followed immediately by injection of 1.5 mL saline over a 10-second period to flush the catheter. Injection of a saline bolus (1.8 mL) verified minimal coronary blood flow (CBF) changes attributable to the injection method. The ranges of doses of ACh and NTG were determined such that increases in LCx coronary blood flow were not accompanied by other hemodynamic effects.
After the control intervention period, when all variables had returned to steady state, a bolus injection of 50 mg lidocaine (Elkins-Sinn) was administered intravenously to minimize the probability of ventricular fibrillation. The snare occluder was then tightened abruptly to completely occlude the LCx for 90 minutes. Ischemia was verified by cessation of CBF velocity, rapid replacement of normal segment shortening by akinesis or dyskinesis as measured by the sonomicrometer crystals implanted in the LCx-perfused region, and/or ST-segment changes in the ECG. At 75 minutes of occlusion, radiolabeled microspheres were again injected via the left atrium to document the extent of LCx blood flow reduction. A second echocardiogram verified dilation of the LV cavity and elimination of systolic wall thickening. In addition, hemodynamic and LV contractility measurements were repeated just before reperfusion.
Animals were randomly assigned to one of three experimental groups on the day of the study, and the investigators were blinded as to the treatment. Five minutes before the onset of reperfusion, dogs (n=6 per group) received a bolus intravenous injection of either the SLeX analog CY-1503 (5 mg/kg), the nonfucosylated analog of SLeX, SLN (5 mg/kg), or an equal volume of 0.9% normal saline. Both CY-1503 and SLN were generously supplied by the Cytel Corporation.
Lidocaine (50 mg IV) was again administered as a bolus injection 2 minutes before release of the LCx occluder. To minimize serious arrhythmia and ventricular fibrillation, reperfusion was initiated by gradual release of the occluder over approximately 5 minutes. Reperfusion was verified by restoration of circumflex CBF velocity and/or increase in segment shortening measured with the sonomicrometer. Hemodynamic and LV function measurements were repeated at 1 and 2 hours of LCx reperfusion. Immediately thereafter, random intracoronary injections of ACh and NTG were administered in doses identical to those administered during the control period. Hemodynamic and contractile data, as well as echocardiography, were again recorded at the end of the 4.5 -hour reperfusion period. Just before the dogs were killed, the LCx was briefly reoccluded and Evans blue dye (Sigma Chemical Co) was injected via the left atrium to delineate the in vivo area at risk. Dogs were then killed with an intravenous bolus injection of saturated potassium chloride. Hearts were rapidly excised for determination of necrosis in vitro.
Postmortem Analysis of Myocardial Necrosis
After excision, the LV (including the interventricular septum) was isolated and cut into 6 to 10 transverse slices, each approximately 5 mm thick. Each slice was weighed and placed into a bath of 4% triphenyltetrazolium chloride (TTC, Sigma Chemical Co) for 30 minutes to determine the extent of myocardial necrosis for each slice. The area at risk of becoming necrotic was defined as the myocardium perfused by the LCx, and was identified by lack of blue staining as well as by presence of a red color (a result of dehydrogenase conversion of TTC to a red formazan). The tissue within the area at risk that lacked any staining (TTC-negative, due to necrosis and loss of dehydrogenase activity) constituted the area of myocardial necrosis.22,23 The slices were traced onto acetate overlays and were scanned onto a Macintosh Ilci computer with a Microtek ScanMaker model 600ZS (Mikrotek Lab, Inc). NIH Image (version 1.41) software was employed to quantify the extent of the specific regions, and each was corrected for the weight of its respective heart slice. The anatomic area at risk was expressed as a percentage of LV, while myocardial necrosis was calculated as a percentage of both area at risk and total LV mass.
Regional Myocardial Blood Flow (MBF) Determination MBF was measured by using 15-,um radioactive-labeled microspheres (E.I. du Pont de Nemours, Inc) by the reference withdrawal method.24 Two injections of microspheres were made in each experiment (baseline and 75 minutes of ischemia), each using one of two isotopes (141Ce; UiSc). Each vial of microspheres was thoroughly mixed by sonication and vortex agitation before injection. Approximately one to two million microspheres were injected directly into the left atrium for each flow measurement. The reference arterial samples were obtained from the catheter inserted into the aorta via the femoral artery; withdrawal of samples began before the injection of microspheres and was maintained at a constant rate for 5 minutes with a Rainin peristaltic pump (Rainin Instrument Co, Inc).
Two adjacent transverse slices of the LV were employed for MBF determinations after overlay tracings were completed for quantification of myocardial necrosis. The two slices selected 
Echocardiographic Analysis
Echocardiographic data were analyzed with a PC-based microcomputer system in a manner similar to that described previously.24 Briefly, echocardiographic recordings were analyzed with a Freeland Systems Cardiology Workstation equipped with CineView version 5.05 analysis package (Prism Imaging, Inc). For each time point studied (baseline, 45 and 75 minutes of occlusion, and 60, 120, and 270 minutes of reperfusion), end-diastolic and end-systolic frames were selected from three successive heartbeats. Endocardial and epicardial borders of the LV were traced electronically on the video display. Values foi end-systolic area (LVESA) and end-diastolic area (LVEDA) from the three cardiac cycles were then averaged, and area ejection fraction (AEF) was calculated as
Determination of Plasma Levels of CY-1503
Peripheral blood samples were collected at 60, 120, 180, and 270 minutes after reperfusion, stored on ice, and centrifuged at 2000g and 4°C for 20 minutes. The plasma was decanted, and levels of CY-1503 were measured using a high-pH anion exchange chromatography method developed at the Cytel Corporation in San Diego, Calif. Strong anion exchange stationary phases take advantage of the weakly acidic nature of carbohydrates to give highly selective separations, while pulsed amperometric detection allows direct analysis of nonderivitized substrates at low levels. The detection of CY-1503 was performed by oxidizing the carbohydrate, which is then absorbed to a partially reduced gold surface. The oxidation signal of the analyte was collected and interpreted as a peak in the elution chromatogram. Quantification of plasma levels of CY-1503 was performed by interpolation from a CY-1503 standard curve.
Briefly, plasma samples (500 ,L) were diluted with 500 ,L of 5% trichloroacetic acid (Fisher Scientific) and incubated on ice for 5 minutes. The samples were then centrifuged in a microcentrifuge (14 000 rpm, 8 minutes) and 800 ,L of the supernatant was removed. The samples were diluted (1:10) and filtered through an Ag ON-Guard preColumn (Dionex) followed by a 0.2-lim filter. The solutions were assayed by using Dionex Ion Chromatography System for Carbohydrate Analysis (BioLC) equipped with a pulsed amperometric detector (Dionex PAD-2 Detector), a CarboPac MA-1 column (4 x 250 mm) with guard column, and a CarboPac PA-1 column (4x250 mm) with guard column. The plasma solutions were assayed at several dilutions until the CY-1503 peak response was within the range of the CY-1503 standard curve. 
Statistical Analysis
All data values in the text, tables, and figures are expressed as mean values+SEM of n independent experiments. CBF changes in response to vasodilator agents were analyzed using paired t tests. All other data, involving repeated measurements and multiple comparisons, were subjected to ANOVA to determine significant intragroup and intergroup differences. Values of P<.05 were considered to be statistically significant.
Results

Hemodynamic Parameters
No significant differences in heart rate (HR), mean arterial blood pressure (MABP), or pressure rate product (PRP) were observed between the three experimental groups at any time point (Table 1) .
LCx blood flow was similar in all three groups under baseline conditions (Table 1) . After experiencing hyperemia early in the LCx reperfusion interval, all three groups exhibited gradual declines in LCx flow. At 4.5-hour reperfusion, LCx flow in both the saline and SLN groups was 39% lower than baseline, while the CY-1503-treated dogs experienced a less-severe reduction (21% below baseline) in LCx flow.
We noted no significant differences between experimental groups in LVSP or in LVEDP at any time point (Table 1 ). All three experimental groups exhibited similar reductions in the peak positive and negative first derivatives of LV pressure (+LVdP/dtmAx and -LVdP/ dtMIN, respectively) during the ischemic period and further declines during the 4.5 -hour reperfusion period. Regional MBF As displayed in Table 2 , there were no intergroup differences under baseline or occlusion conditions in either ischemic zone or nonischemic zone transmural MBF. Relative to the respective values measured at baseline, ischemic zone blood flow was reduced by 91% during occlusion in the saline group, by 96% in the SLN group, and by 90% in the CY-1503 treatment group (P=NS between groups). In addition, there were no significant differences in the subendocardial, mid-myocardial, or subepicardial blood flow between the groups in the ischemic or nonischemic zones at baseline or during occlusion.
Effect of CY-1503 on CK Activity Neutrophil infiltration into the myocardium, as quantified through MPO activity, was measured in nonischemic, ischemic-reperfused, and necrotic tissue taken from each heart. MPO values in the nonischemic region were not significantly different between the three experimental groups (Fig 4) . In all groups, MPO was elevated in the ischemic region when compared with the respective nonischemic tissue; however, MPO value in the CY-1503-treated ischemic tissue was only 50% of that in either saline-or SLN-treated dogs ( 
Regional Myocardial Contractile Function
Regional myocardial contractility was expressed as percent segment shortening (%SS) and was measured in the ischemic-reperfused (LCx) and nonischemic (LAD) zones. In both the ischemic-reperfused and nonischemic regions, there were no significant differences between any of the experimental groups at any of the time points. Fig 7, right, left. We observed no significant differences between groups, and none of the experimental groups exhibited appreciable changes from baseline nonischemic zone %SS over the time course of the experiments.
Global Myocardial Contractility Two-dimensional short-axis echocardiography revealed similar LV functional impairment after 75 minutes of LCx occlusion in all three groups (Fig 8) . In each group of dogs, dilation of the LV during occlusion was evidenced by concurrent increases in both LV end-diastolic area and LV end-systolic area (data not shown). Most notably, area ejection fraction was significantly attenuated during occlusion by approximately 50% in every group. Echocardiograms performed at 270 minutes of reperfusion (Fig 8) revealed no intergroup differences and similar degrees of myocardial stunning; in each group, area ejection fraction remained significantly depressed compared with its respective baseline value.
Circulating Leukocyte and Neutrophil Counts
The total circulating leukocyte and neutrophil counts for the saline, SLN, and CY-1503 dogs at baseline, occlusion, and reperfusion are presented in Table 3 . While total leukocytes and neutrophils were comparable in the saline and SLN groups at baseline, the dogs in the CY-1503 group exhibited significantly greater (P<.05) total leukocyte and neutrophil counts compared with the saline and SLN groups. Both total leukocyte and neutrophil counts increased after coronary artery occlusion in all three groups. Furthermore, total leukocyte and neutrophil counts increased further during the 4.5-hour reperfusion period to similar levels in all three groups studied. Interestingly, both leukocyte and neutrophil counts increased significantly (P<.05) from baseline in the SLN-and CY-1503-treated animals at 2 and 4.5 hours of reperfusion. In contrast, total leukocyte and neutrophil counts increased in the saline reperfusion. MAb R15.7 also has been studied in isolated rat hearts subjected to ischemia and reperfusion, and the results of this study also demonstrate a reduction in postischemic myocardial injury.7 In contrast to these studies, Tanaka et a132 determined that the anti-CD18 MAb IB4 failed to limit myocardial infarct size in canines subjected to coronary artery occlusion and reperfusion. Additional studies have examined the efficacy of anti-ICAM-1 MAbs12-14 in a number of animal models of myocardial ischemia and reperfusion. Such studies demonstrated that anti-ICAM-1 MAbs substantially reduced myocardial necrosis after coronary artery occlusion and reperfusion in cats,13 rats,14 and nonhuman primates. 12 A recent experimental investigation of an MAb directed against P-selectin15 provides evidence that Pselectin may mediate the early PMN-endothelial interactions after myocardial ischemia and reperfusion. P-selectin is normally presynthesized and stored within the Weibel-Palade bodies of endothelial cells and within the a-granules of platelets.33-36 After stimulation with thrombin, histamine, platelet activating factor, and other stimuli, P-selectin is rapidly mobilized to the surface of endothelial cells and platelets and thereby mediates neutrophil-endothelial, platelet-endothelial, and platelet-neutrophil interactions.3738 Weyrich et a115 reported prominent P-selectin immunostaining in the coronary circulation of cats after 90 minutes of ischemia and 20 minutes of reperfusion, whereas myocardium subjected to 90 minutes of ischemia and 4.5 hours of reperfusion failed to exhibit P-selectin immunoreactivity. These investigators also demonstrated that a novel anti-P-selectin MAb, PB1.3, preserved coronary vascular integrity and significantly reduced myocardial necrosis after 90 minutes of myocardial ischemia and 4. The myocardial protection that we observed in the present study cannot be attributed to a lesser severity of myocardial ischemia in the CY-1503-treated group, as the reductions in ischemic zone MBF and the areas of myocardium placed at risk by LCx occlusion were comparable in the three study groups. Furthermore, the degree of regional and global myocardial contractile dysfunction during coronary occlusion was similar in the three experimental groups, which also suggests a comparable ischemic insult. It is important to note that CY-1503 reduced the degree of myocardial necrosis over a broad range of ischemic zone MBFs (Fig 3, left) and the protective effects of CY-1503 were not confined to higher levels of MBF indicative of less-severe ischemia. Thus, CY-1503 was found to reduce myocardial necrosis in this experimental model regardless of the severity of myocardial ischemia. In addition, CY-1503 treatment did not reduce the number of circulating neutrophils and thereby induce myocardial protection. In fact, dogs treated with CY-1503 exhibited the highest neutrophil counts at baseline, occlusion, and throughout reperfusion.
Whereas an MAb can inhibit a single adhesion glycoprotein, treatment with CY-1503 offers the advantage that it might effectively block the actions of all of the selectins simultaneously and could completely inhibit selectin-mediated "rolling" of PMNs along the ischemic-reperfused coronary endothelium. In the present study we are uncertain which of the selectins mediates the profound vascular and myocardial injury that was observed in dogs receiving saline or SLN. The results of the present study do provide experimental evidence that selectins are involved in postischemic myocardial injury and suggest a novel therapeutic approach to reduce reperfusion-induced myocardial injury. One major limitation of the present study is the limited time period of reperfusion that we investigated. It would be extremely valuable to study the effects of treatment with CY-1503 after myocardial ischemia and longer periods of reperfusion (ie, 24 or 48 hours) to determine whether this SLex analog reduces the extent of myocardial infarct development or merely delays the onset of myocardial injury and infarction. Although CY-1503 treatment resulted in a dramatic reduction in coronary vascular injury and myocardial necrosis, we did not observe any improvement in regional or global myocardial contractility at any time during the reperfusion interval. This would suggest that ischemic-reperfused myocytes, although salvaged by CY-1503 administration, were viable but "stunned" and therefore unable to maintain normal myocardial function. It is conceivable that if reperfusion were carried out for days or weeks these "stunned" yet viable myocytes might recover more fully from ischemia-reperfusion injury, eventually resulting in significant improvement in myo-cardial contractility compared with hearts receiving saline or the inactive carbohydrate SLN.
In summary, we have demonstrated that the administration of a pentasaccharide analog of SLeX attenuates myocardial injury after 90 minutes of regional ischemia and 4.5 hours of reperfusion in anesthetized, open-chest dogs. Administration of a fucose-deficient analog of CY-1503 did not result in any myocardial preservation and suggests that fucose is required for the observed cardioprotection. Additional studies using nonsialylated carbohydrates are necessary to elucidate the potential role of sialic acid in the inhibitory actions of SLeX in myocardial reperfusion injury. SLex-related carbohydrates may prove beneficial in the treatment of inflammatory diseases in which selectin-mediated PMN adhesion contributes to tissue injury.
